A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 May 2018

At a glance

  • Drugs NP 213 (Primary)
  • Indications Onychomycosis
  • Focus Therapeutic Use
  • Sponsors Taro Pharmaceuticals USA
  • Most Recent Events

    • 17 May 2018 Planned End Date changed from 1 May 2018 to 1 Jun 2018.
    • 17 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 May 2018.
    • 17 May 2018 According to a Taro Pharmaceuticals Inc media release, this trial did not meet the main goal and the study data is being analysed to determine next course of action in the program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top